Care, Capacity and Cash Flows: Dawgen CARI-VAL Health™ for Valuing Healthcare Businesses in the Caribbean

Hospitals, clinics, diagnostic labs, pharmacies, medical suppliers and healthtech platforms sit at the heart of well-being, productivity and social stability. In Jamaica, the wider Caribbean, and Latin America & the Caribbean (LAC), the healthcare sector is also:

• A major employer

• A significant consumer of public budgets

• A growing area for private investment, PPPs and insurance partnerships

So it’s no surprise that boards, lenders, investors, families and governments routinely ask:

“What is this hospital, clinic, lab or healthcare group really worth?”

The answer is rarely straightforward.

Healthcare entities operate at the crossroads of:

• Medicine and technology

• Public policy and private investment

• Regulated pricing and market forces

• Long-lived infrastructure and fast-changing clinical practice

Traditional shortcuts – “x times EBITDA” or “rebuild cost of the hospital” – routinely miss critical drivers of value and risk.

To provide a more robust, sector-aware approach, Dawgen Global has developed Dawgen CARI-VAL Health™, a healthcare-focused adaptation of our broader Dawgen CARI-VAL™ Sector Valuation Series. It is designed to value:

• Private hospitals and day-surgery centres

• Specialist and multi-specialty clinics

• Diagnostic imaging and laboratory networks

• Pharmacies and pharmaceutical distributors

• Medical device and supplies businesses

• Healthtech and digital health platforms

with a sharp focus on Caribbean and LAC realities.

This article sets out the Dawgen CARI-VAL Health™ framework and explains how it supports decision-ready valuations for healthcare businesses.

1. Why Healthcare Valuation Is Different

Healthcare is not just another service sector. Several features make valuation uniquely complex:

1. Dual mission: clinical outcomes and financial sustainability

   • The ultimate “output” is health and lives, not just revenue.

   • Yet facilities must remain financially viable and fund reinvestment.

2. Heavy regulation and political sensitivity

   • Licensing, accreditation, clinical protocols and pricing are tightly regulated.

   • Healthcare decisions are often politically visible and emotionally charged.

3. Multiple payers and complex reimbursement

   • Public schemes, private insurers, employers, out-of-pocket patients and medical tourism all intersect.

   • Revenue depends on reimbursement rules, benefit designs, negotiations and approval processes.

4. Capital intensity and specialised infrastructure

   • Hospitals and diagnostic centres require substantial investment in buildings, equipment and technology.

   • Equipment becomes obsolete; standards and protocols evolve.

5. Human capital and reputation

   • Doctors, nurses, technicians and management drive outcomes and patient loyalty.

   • Brand and reputation (quality, safety, trust) are central but intangible.

A serious valuation must therefore integrate regulation, payor dynamics, capacity, clinical mix, technology, workforce and reputation, not just the last set of financial statements.

That is what Dawgen CARI-VAL Health™ is designed to do.

2. The Dawgen CARI-VAL Health™ Framework

The CARI-VAL family is built around seven pillars:

• C – Context & Cycle

• A – Assets & Advantage

• R – Risks, Regulation & Resilience

• I – Intangibles, Innovation & Integration

• V – Value Drivers & Financial Engine

• A – Alternative Scenarios & Stress Tests

• L – Liquidity, Listings & Exit

For healthcare, we adapt this into Dawgen CARI-VAL Health™, with sector-specific lenses and metrics at each stage.

3. C – Context & Cycle: Health System, Demographics and Demand

Valuation begins with understanding the health system and population the provider serves.

3.1 Demographic and Epidemiological Context

We assess:

• Population size, age profile and urbanisation

• Burden of disease: NCDs (diabetes, hypertension, cardiovascular disease), injuries, maternal and child health, infectious diseases

• Life expectancy and health-seeking behaviour

Ageing populations and high NCD prevalence can drive demand for chronic care, diagnostics and specialist services.

3.2 Health System Structure

We look at:

• Balance between public and private provision

• Role of private providers in:

  • Primary care

  • Secondary and tertiary care

  • Diagnostics and pharmacy

• Availability of public insurance, private insurance and employer schemes

The degree to which private providers operate as complements to public systems (relieving pressure) or substitutes (direct competition) shapes demand and pricing power.

3.3 Economic, Tourism and Medical Travel Dynamics

We consider:

• Income levels and health expenditure per capita

• Growth in medical tourism and expatriate communities

• Importance of tourism and hospitality (driving demand for emergency and elective care from visitors)

Hospitals or clinics positioned to serve regional patients or medical tourists may warrant different growth and margin assumptions.

4. A – Assets & Advantage: Facilities, Technology and Service Mix

Next, we examine the hard and soft assets that underpin service delivery.

4.1 Facilities and Capacity

We analyse:

• Number of beds, operating theatres, procedure rooms

• Ambulatory vs inpatient capacity

• Location and accessibility (urban vs peri-urban, proximity to transport hubs, catchment area)

• Facility condition, design and ability to support modern clinical workflows

We ask whether current infrastructure is:

• Adequate and well-utilised

• Under-sized relative to demand

• Outdated or poorly configured, requiring major refurbishment

4.2 Medical Equipment and Technology

We review:

• Imaging equipment (X-ray, CT, MRI, ultrasound), lab analysers, operating theatre equipment, ICU and monitoring technology

• Age profile, maintenance regime and uptime

• Compliance with current clinical standards and radiation safety requirements

Modern, reliable equipment supports higher-quality care, revenue growth and referral relationships.

4.3 Service Lines and Clinical Scope

We map:

• Core service lines: emergency, internal medicine, surgery, obstetrics, paediatrics, orthopaedics, oncology, cardiology, etc.

• Breadth and depth of diagnostics: imaging, pathology, specialised tests

• Ancillary services: physiotherapy, dialysis, day surgery, wellness, occupational health

We differentiate between:

• Providers focused on core, high-demand services, and

• Providers with broader, complex or specialised portfolios that require higher expertise and capital but may command better margins.

4.4 Integration Across the Care Pathway

We assess:

• Linkages between primary, secondary, diagnostic and pharmacy services

• Relationships with referring physicians and clinics

• Care coordination for chronic disease management

Better integration often translates into more stable demand, higher patient loyalty and improved outcomes.

5. R – Risks, Regulation & Resilience

Healthcare is one of the most regulated and risk-sensitive sectors.

5.1 Licensing, Accreditation and Compliance

We consider:

• Licensing status and scope for each facility and service line

• Accreditation (national, regional or international)

• Compliance with health, safety, infection control and data protection requirements

• History of warnings, sanctions or closures

Regulatory non-compliance can directly affect value through operational restrictions, reputational damage and corrective capex.

5.2 Clinical, Legal and Ethical Risk

We examine:

• Clinical governance frameworks and treatment protocols

• Incident reporting, root-cause analysis and corrective action systems

• Malpractice claims history and insurance coverage

• Informed consent and patient rights practices

Effective clinical governance reduces the likelihood and severity of adverse events and legal claims, which can significantly affect valuations.

5.3 Payor and Reimbursement Risk

We analyse:

• Revenue split by payor type:

  • Out-of-pocket

  • Public schemes

  • Private insurers

  • Employers

  • Overseas payors / medical tourism

• Tariff structures, reimbursement schedules and approval processes

• Negotiating power with insurers and large payors

• Exposure to delayed payments or write-offs

Revenue concentration in one or two payors, or heavy reliance on underfunded schemes, may warrant higher risk adjustments.

5.4 Operational and Business Continuity Risk

We look at:

• Reliance on a few key doctors or specialists

• Workforce availability (nurses, technicians, pharmacists)

• Capacity to operate during shocks (pandemics, disasters, strikes)

• Backup power, water, IT and supply chain arrangements

Facilities that demonstrate operational resilience can maintain service and revenue even in challenging conditions.

6. I – Intangibles, Innovation & Integration

Much of healthcare value resides in intangibles and relationships, not just buildings and equipment.

6.1 Brand, Reputation and Patient Trust

We evaluate:

• Community perception of quality, safety and affordability

• Referral patterns from physicians and allied health professionals

• Patient satisfaction and complaint trends

• Online presence and ratings where relevant

Trust is central: patients and physicians choose providers they believe in, which drives volumes and pricing power.

6.2 Clinical Talent and Organisational Culture

We consider:

• Depth and stability of the medical staff (consultants, specialists, GPs)

• Nursing and allied health workforce engagement and turnover

• Culture of teamwork, learning and continuous improvement

• Dependence on a few “star” consultants vs institutional strength

Strong teams and culture reduce key-person risk and support consistent quality.

6.3 Innovation and Digital Health

We examine:

• Use of electronic medical records (EMR) and digital diagnostic systems

• Telemedicine, remote monitoring and virtual care offerings

• Patient portals, appointment and payment apps, digital engagement

• Data and analytics use for clinical quality, operations and resource planning

Digitally-enabled providers tend to have better efficiency, patient experience and data for decision-making, which support value.

6.4 Integration with the Wider Health Ecosystem

We look at:

• Partnerships with public facilities, universities and teaching hospitals

• Collaborations with insurers, employers and wellness programmes

• Role in national screening initiatives or disease management programmes

Providers deeply integrated into the health ecosystem often enjoy more stable demand and stronger stakeholder support.

7. V – Value Drivers & Financial Engine

Once the context and intangibles are understood, we turn to the numbers behind the business.

7.1 Revenue Drivers and Mix

We break down:

• Revenue by service line (inpatient, outpatient, diagnostics, pharmacy, procedures, packages)

• Revenue by payor type and geography (local vs foreign patients)

• Case mix and complexity – routine vs higher-acuity services

• Volume trends: admissions, bed-days, outpatient visits, scans, tests, procedures

We look for:

• Sustainable drivers of growth vs one-off spikes

• Balance between high-volume / lower-margin services and specialised / higher-margin services

• Exposure to seasonal patterns (e.g. tourism-linked services)

7.2 Capacity Utilisation and Unit Economics

We analyse:

• Bed occupancy rates and average length of stay

• Theatre utilisation (hours used vs available)

• Utilisation of imaging and lab equipment (scans/tests per machine)

• Throughput per doctor, nurse or technician where appropriate

Underutilised assets may represent latent upside – or evidence of misalignment between capacity and demand.

7.3 Cost Structure and Margins

We examine:

• Staff costs (clinical and non-clinical)

• Consumables, pharmaceuticals and medical supplies

• Utilities and facilities costs

• Maintenance and service contracts for equipment

• IT, administration and overhead

We assess:

• Gross margins by service line

• EBITDA and EBIT margins

• Sensitivity of margins to staffing levels, case mix and input prices

This highlights true value drivers and efficiency levers.

7.4 Working Capital and Cash Conversion

Healthcare businesses can appear profitable but struggle with cash:

• Receivables from insurers, public schemes and corporate clients

• Credit terms with suppliers of pharmaceuticals and consumables

• Inventory levels (medications, supplies, reagents, implants)

We analyse:

• Days sales outstanding (DSO) and ageing

• Inventory days and obsolescence risk

• Payables days and reliance on supplier finance

Cash conversion is crucial for funding capex and growth.

7.5 Capital Expenditure and Renewal

We model:

• Maintenance capex – routine replacement of equipment, refurbishment of wards, theatres and clinics

• Regulatory-driven capex – compliance with new standards or requirements

• Expansion capex – new services, additional beds, satellite clinics, digital investments

Healthcare is capex-intensive; realistic modelling avoids inflated valuations based on under-invested asset bases.

7.6 Valuation Approaches

Under Dawgen CARI-VAL Health™, we typically employ a combination of:

1. Discounted Cash Flow (DCF)

   • Projecting free cash flows, incorporating realistic assumptions about volumes, tariffs, case mix, payor dynamics, staff costs, consumables and capex.

2. Market Multiples

   • EV/EBITDA, EV/EBIT, P/E, sometimes revenue multiples for high-growth healthtech platforms.

   • Benchmarked against local, regional and global healthcare comps, then adjusted for size, risk, country factors and payor mix.

3. Asset-Based Cross-Checks

   • Relevant for hospital real estate and major equipment – particularly when earnings are temporarily depressed or service mix is changing.

4. Per-Bed / Per-Facility Metrics

   • In some contexts, benchmarks (value per bed, per theatre, per scanner) supplement primary methods, though we avoid relying on them alone.

All methods are grounded in the CARI-VAL Health™ diagnostic, not used mechanically.

8. A – Alternative Scenarios & Stress Tests

Healthcare valuations must account for policy changes, shocks and evolving demand.

8.1 Scenario Planning

We normally build:

• Base Case – aligned with realistic growth in patient volumes and tariffs, moderate shifts in case mix, and planned investments.

• Upside Case – successful expansion, new service lines, improved payor mix, increased occupancy and productivity.

• Downside Case – reimbursement pressure, regulatory changes, staff shortages, or loss of key specialists or contracts.

We adjust:

• Volume, pricing and case mix assumptions

• Staff cost and consumables inflation

• Capex and working capital needs

• Discount rates and exit multiples

8.2 Stress Testing

We also test shocks such as:

• Delayed payments or tariff cuts from public or private payors

• Departure of key specialists or management

• Need for major compliance-driven capex (facility upgrades, equipment replacement)

• Adverse events affecting reputation and volumes

• Pandemics or disasters impacting elective procedures and normal operations

This gives boards, lenders and investors a clear view of downside risk, resilience and required buffers, not just a single-point valuation.

9. L – Liquidity, Listings & Exit

The final pillar explores who might buy a healthcare business, how, and with what expectations.

9.1 Buyer Universe

Potential buyers include:

• Regional and international healthcare groups

• Local and regional conglomerates expanding into healthcare

• Private equity and impact investors

• Health insurers or strategic partners

• Doctor groups and management teams (MBO/MBI structures)

Each buyer perceives synergies, risk and strategic value differently, affecting price and deal structure.

9.2 Control vs Minority Stakes

We distinguish between:

• Full control transactions – enabling changes in strategy, service mix, capital structure, partnerships and digital investments;

• Significant minority investments – where influence depends on governance arrangements;

• Passive minority stakes – often illiquid and dependent on existing management.

Control positions typically warrant higher valuations; illiquid minority stakes in tightly held family or doctor-owned entities may attract discounts.

9.3 Capital Markets and Platform Strategies

We consider:

• Potential to build multi-facility or multi-country healthcare platforms

• Scope for listing healthcare groups on local or regional exchanges

• Appetite among investors for defensive, yield-oriented healthcare stories with growth potential

Exit options and platform potential feed into discount rate selection and strategic recommendations.

10. How Dawgen Global Uses CARI-VAL Health™ in Practice

We apply Dawgen CARI-VAL Health™ across a wide range of healthcare engagements:

• M&A, Transactions and Partnerships

  • Valuations for acquisitions, disposals, joint ventures and strategic alliances involving hospitals, clinics, labs, pharmacies and distributors.

  • Independent value opinions for boards, committees and regulators.

• Financing, Refinancing and Restructuring

  • Valuations for banks, DFIs and private lenders financing healthcare entities.

  • Support for restructuring, recapitalisation or portfolio clean-up.

• Strategic Reviews and Expansion Planning

  • Assessing where value is created across service lines and locations.

  • Supporting decisions on new facilities, service upgrades, digital investments and PPPs.

• Succession and Family Business Planning

  • Valuations for doctor-owned and family-owned healthcare entities to support inter-generational transfers, buy-outs and estate planning.

What differentiates our approach is the combination of sector-specific understanding, valuation discipline and regional insight — all structured through the Dawgen CARI-VAL™ methodology.

Next Step: Put a Clear Value on Your Healthcare Decisions

If you are:

• A hospital, clinic, lab or pharmacy owner considering expansion, succession, sale or partnership,

• A healthcare group or insurer evaluating acquisitions or integrated care models,

• A bank, investor or DFI financing healthcare projects and needing independent valuations, or

• A public agency or PPP unit assessing private participation in health services,

…you need more than a simple multiple or building valuation.

The Dawgen CARI-VAL Health™ Framework offers a structured, transparent and region-aware approach to valuing healthcare businesses — integrating clinical, operational, regulatory and financial realities into one coherent picture.

To explore how Dawgen Global can support your healthcare valuation, strategy or transaction needs:

📧 Email: [email protected]
📱 WhatsApp (Global): +1 555 795 9071

At Dawgen Global, we help you make Smarter and More Effective Valuation Decisions — strengthening healthcare systems across Jamaica, the Caribbean and the wider LAC region.